|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2009-12-10
|
|
pubmed:abstractText |
Nebivolol is a highly selective beta-adrenoreceptor antagonist with vasodilating properties. This study investigated its effect on quality of life (QoL) and blood pressure (BP) in real life conditions. In total, 1468 patients were enrolled, 12% diabetics. Nebivolol was prescribed as monotherapy, add-on or switch medication.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0803-8023
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
1
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5-14
|
|
pubmed:meshHeading |
pubmed-meshheading:20050100-Adrenergic beta-Antagonists,
pubmed-meshheading:20050100-Adult,
pubmed-meshheading:20050100-Aged,
pubmed-meshheading:20050100-Antihypertensive Agents,
pubmed-meshheading:20050100-Benzopyrans,
pubmed-meshheading:20050100-Diabetes Mellitus,
pubmed-meshheading:20050100-Ethanolamines,
pubmed-meshheading:20050100-Female,
pubmed-meshheading:20050100-Humans,
pubmed-meshheading:20050100-Hypertension,
pubmed-meshheading:20050100-Male,
pubmed-meshheading:20050100-Middle Aged,
pubmed-meshheading:20050100-Prospective Studies,
pubmed-meshheading:20050100-Quality of Life
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. the QoLaN study.
|
|
pubmed:affiliation |
Department of endocrinology and Nutrition, St-Luc University Hospital, Catholic University of Louvain, Brussels, Belgium. michel.hermans@diab.ucl.ac.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
